Hansoh Pharmaceutical and Roche Sign ADC Strategic Collaboration and License Deal Worth Over $15.5 Billion

Hansoh Pharmaceutical announced that its wholly owned subsidiaries have entered a strategic collaboration and license agreement with Roche for antibody-drug conjugate (ADC) programs, with a total deal value exceeding $15.5 billion. This is the parties' second collaboration in the ADC field. Roche will handle further development worldwide, excluding mainland China, Hong Kong, Macau and Taiwan, where Hansoh retains all rights to develop, register and commercialize the programs.